VERACYTE (VCYT) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$45.23
+3.7% on the day
+29.5% over 12 months
52-week range $30.01 – $60.49
Share price and insider trades
VCYT closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$21.0M
Insiders buying0
Insiders selling11
VERACYTE insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $21.0M of VCYT stock on the open market.
Get emailed when insiders cluster-buy stocks like VCYT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
VCYT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.3M | 9 |
| Q2 2026 | — | 0 | $10.1M | 12 |
| Q1 2026 | — | 0 | $3.2M | 8 |
| Q4 2025 | — | 0 | $7.7M | 32 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 VERACYTE, INC. insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $21.0M. 58 of 61 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 22SEC | John LeiteGlobal Chief Commercial Off | Sell Plan | 4,015124,329 held (−3%) | $40.00 | $161K | +13.1% | — |
| Sep 16SEC | Jens HolsteinDirector | Sell Plan | 5,00027,471 held (−15%) | $40.95 | $205K | +10.5% | — |
| Sep 4SEC | Phillip G. FebboChief Scientific & Med Officer | Sell Plan | 10,405135,753 held (−7%) | $42.89 | $446K | +5.5% | — |
| Sep 4SEC | Phillip G. FebboChief Scientific & Med Officer | Sell Plan | 2,705133,048 held (−2%) | $43.66 | $118K | +3.6% | — |
| Sep 4SEC | Rebecca ChambersCFO | Sell Plan | 2,477167,200 held (−1%) | $42.81 | $106K | +5.7% | — |
| Sep 4SEC | Annie McguireGeneral Counsel | Sell Plan | 2,154132,260 held (−2%) | $42.79 | $92K | +5.7% | — |
| Sep 4SEC | Rebecca ChambersCFO | Sell Plan | 1,175166,025 held (−1%) | $43.71 | $51K | +3.5% | — |
| Sep 4SEC | Annie McguireGeneral Counsel | Sell Plan | 1,100131,160 held (−1%) | $43.67 | $48K | +3.6% | — |
| Sep 3SEC | Muna BhanjiDirector | Sell Plan | 1,86442,718 held (−4%) | $42.97 | $80K | +5.3% | — |
| Jun 22SEC | Karin EasthamDirector | Sell Plan | 3,20015,626 held (−17%) | $52.78 | $169K | -14.3% | — |
| Jun 22SEC | Karin EasthamDirector | Sell Plan | 52915,097 held (−3%) | $53.55 | $28K | -15.5% | — |
| Jun 4SEC | Marc StapleyCEO | Sell Plan | 138,051440,494 held (−24%) | $50.12 | $6.9M | -9.8% | — |
| Jun 4SEC | John LeiteGlobal Chief Commercial Off | Sell Plan | 13,975132,305 held (−10%) | $50.07 | $700K | -9.7% | — |
| Jun 4SEC | Rebecca ChambersCFO | Sell Plan | 1,961173,280 held (−1%) | $50.09 | $98K | -9.7% | — |
| Jun 4SEC | Annie McguireGeneral Counsel | Sell Plan | 1,776137,240 held (−1%) | $50.12 | $89K | -9.8% | — |
| Jun 4SEC | Rebecca ChambersCFO | Sell Plan | 1,600175,241 held (−1%) | $49.28 | $79K | -8.2% | — |
| Jun 4SEC | Annie McguireGeneral Counsel | Sell Plan | 1,400139,016 held (−1%) | $49.31 | $69K | -8.3% | — |
| May 27SEC | Jonathan WygantVp, Chief Accounting Officer | Sell | 24,00045,434 held (−35%) | $45.40 | $1.1M | -0.4% | — |
| May 22SEC | Robert S EpsteinDirector | Sell Plan | 10,00052,446 held (−16%) | $44.01 | $440K | +2.8% | — |
| May 8SEC | Annie McguireGeneral Counsel | Sell Plan | 5,102143,708 held (−3%) | $40.00 | $204K | +13.1% | — |
| May 8SEC | Annie McguireGeneral Counsel | Sell Plan | 5,102148,810 held (−3%) | $38.05 | $194K | +18.9% | — |
| Mar 6SEC | Marc StapleyCEO | Sell Plan | 26,279357,554 held (−7%) | $36.28 | $953K | +24.7% | — |
| Mar 6SEC | Marc StapleyCEO | Sell Plan | 19,244383,833 held (−5%) | $35.56 | $684K | +27.2% | — |
| Mar 6SEC | Rebecca ChambersCFO | Sell Plan | 13,941131,196 held (−10%) | $36.33 | $506K | +24.5% | — |
| Mar 6SEC | John LeiteChief Commercial Officer-Clia | Sell Plan | 5,260107,580 held (−5%) | $35.19 | $185K | +28.5% | — |
| Mar 6SEC | Annie McguireGeneral Counsel | Sell Plan | 4,99496,370 held (−5%) | $35.29 | $176K | +28.2% | — |
| Mar 6SEC | Rebecca ChambersCFO | Sell Plan | 4,400145,137 held (−3%) | $35.55 | $156K | +27.2% | — |
| Mar 6SEC | Annie McguireGeneral Counsel | Sell Plan | 1,66494,706 held (−2%) | $36.34 | $60K | +24.5% | — |
| Mar 4SEC | Phillip G. FebboChief Scientific & Med Officer | Sell Plan | 13,425117,346 held (−10%) | $36.16 | $485K | +25.1% | — |
| Dec 17SEC | Annie McguireGeneral Counsel | Sell Plan | 10,63967,860 held (−14%) | $43.13 | $459K | +4.9% | — |
| Dec 17SEC | Annie McguireGeneral Counsel | Sell Plan | 10067,760 held (−0%) | $43.68 | $4K | +3.5% | — |
| Dec 8SEC | Karin EasthamDirector | Sell Plan | 12,80814,354 held (−47%) | $45.84 | $587K | -1.3% | — |
| Dec 8SEC | Karin EasthamDirector | Sell Plan | 6,39227,162 held (−19%) | $44.52 | $285K | +1.6% | — |
| Dec 8SEC | Karin EasthamDirector | Sell Plan | 80013,554 held (−6%) | $46.59 | $37K | -2.9% | — |
| Dec 4SEC | Rebecca ChambersCFO | Sell Plan | 8,537114,237 held (−7%) | $46.61 | $398K | -3.0% | — |
| Dec 4SEC | Rebecca ChambersCFO | Sell Plan | 4,741109,496 held (−4%) | $47.25 | $224K | -4.3% | — |
| Dec 4SEC | Marc StapleyCEO | Sell Plan | 4,448321,823 held (−1%) | $46.90 | $209K | -3.6% | — |
| Dec 4SEC | Marc StapleyCEO | Sell Plan | 3,220318,603 held (−1%) | $47.35 | $152K | -4.5% | — |
| Dec 4SEC | John LeiteChief Commercial Officer-Clia | Sell Plan | 1,27882,113 held (−2%) | $47.51 | $61K | -4.8% | — |
| Dec 4SEC | Annie McguireGeneral Counsel | Sell Plan | 72079,201 held (−1%) | $47.10 | $34K | -4.0% | — |
| Dec 4SEC | Annie McguireGeneral Counsel | Sell Plan | 70278,499 held (−1%) | $47.51 | $33K | -4.8% | — |
| Nov 26SEC | John LeiteChief Commercial Officer-Clia | Sell Plan | 2,80886,291 held (−3%) | $50.00 | $140K | -9.5% | — |
| Nov 26SEC | Evan/ Fa JonesDirector | Sell Plan | 1,10629,362 held (−4%) | $50.25 | $56K | -10.0% | — |
| Nov 21SEC | Jens HolsteinDirector | Sell Plan | 7,04928,659 held (−20%) | $42.48 | $299K | +6.5% | — |
| Nov 21SEC | Jens HolsteinDirector | Sell Plan | 1,46027,199 held (−5%) | $43.21 | $63K | +4.7% | — |
| Nov 21SEC | Jens HolsteinDirector | Sell Plan | 1,49135,708 held (−4%) | $40.95 | $61K | +10.5% | — |
| Nov 12SEC | Jonathan WygantVp, Chief Accounting Officer | Sell | 5,81843,847 held (−12%) | $40.21 | $234K | +12.5% | — |
| Nov 12SEC | Jonathan WygantVp, Chief Accounting Officer | Sell | 5,10238,745 held (−12%) | $42.33 | $216K | +6.9% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 24,29631,125 held (−44%) | $45.73 | $1.1M | -1.1% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 10,83761,293 held (−15%) | $43.80 | $475K | +3.3% | — |
| Nov 7SEC | Karin EasthamDirector | Sell Plan | 9,67413,554 held (−42%) | $40.02 | $387K | +13.0% | — |
| Nov 7SEC | Rebecca ChambersCFO | Sell Plan | 7,000126,158 held (−5%) | $41.00 | $287K | +10.3% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 5,87255,421 held (−10%) | $45.07 | $265K | +0.4% | — |
| Nov 7SEC | Annie McguireGeneral Counsel | Sell Plan | 6,46682,973 held (−7%) | $40.00 | $259K | +13.1% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 1,12672,130 held (−2%) | $43.03 | $48K | +5.1% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 65730,468 held (−2%) | $46.38 | $30K | -2.5% | — |
| Nov 7SEC | Evan/ Fa JonesDirector | Sell Plan | 40873,256 held (−1%) | $41.74 | $17K | +8.4% | — |
| Oct 7SEC | Phillip G. FebboChief Scientific & Med Officer | Sell Plan | 8,34992,441 held (−8%) | $36.02 | $301K | +25.6% | — |
| Oct 3SEC | Robert S EpsteinDirector | Sell Plan | 21,47362,446 held (−26%) | $35.08 | $753K | +28.9% | — |
| Oct 3SEC | John LeiteChief Commercial Officer-Clia | Sell Plan | 2,53989,099 held (−3%) | $35.00 | $89K | +29.2% | — |
| Oct 3SEC | Annie McguireGeneral Counsel | Sell Plan | 2,16089,439 held (−2%) | $35.00 | $76K | +29.2% | — |
Insiders at VERACYTE, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Marc StapleyCEO | — | $8.9M | Jun 4, 2026 | — |
| Evan/ Fa JonesDirector | — | $2.0M | Nov 26, 2025 | — |
| Rebecca ChambersCFO | — | $1.9M | Sep 4, 2026 | — |
| Annie McguireGeneral Counsel | — | $1.8M | Sep 4, 2026 | — |
| Jonathan WygantVp, Chief Accounting Officer | — | $1.5M | May 27, 2026 | — |
| Karin EasthamDirector | — | $1.5M | Jun 22, 2026 | — |
| Phillip G. FebboChief Scientific & Med Officer | — | $1.4M | Sep 4, 2026 | — |
| John LeiteGlobal Chief Commercial Off | — | $1.3M | Sep 22, 2026 | — |
| Robert S EpsteinDirector | — | $1.2M | May 22, 2026 | — |
| Jens HolsteinDirector | — | $628K | Sep 16, 2026 | — |
| Muna BhanjiDirector | — | $80K | Sep 3, 2026 | — |
VCYT stock: common questions
Are VERACYTE, INC. insiders buying VCYT stock?
In the past 12 months, 0 insiders reported open-market purchases of VCYT worth $0.
Are VERACYTE, INC. insiders selling VCYT stock?
11 insiders reported sales worth $21.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is VCYT's 52-week range?
Over the past year VCYT has traded between $30.01 and $60.49. It last closed at $45.23 on Oct 9, 2026.